A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Myron S. Czuczman; Marek Trněný; Andrew Davies; Simon Rule; Kim M. Linton; Nina Wagner-Johnston; Randy D. Gascoyne; Graham W. Slack; Pierre Brousset; David A. Eberhard; Francisco J. Hernandez-Ilizaliturri; Gilles Salles; Thomas E. Witzig; Pier Luigi Zinzani; George W. Wright; Louis M. Staudt; Yandan Yang; P. Mickey Williams; Chih-Jian Lih; Jacqueline Russo; Anjan Thakurta; Patrick Hagner; Pierre Fustier; Dale Song; Ian D. Lewis

doi:10.1158/1078-0432.ccr-16-2818

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-16-2818 ◽

2017 ◽

Vol 23 (15) ◽

pp. 4127-4137 ◽

Cited By ~ 64

Author(s):

Myron S. Czuczman ◽

Marek Trněný ◽

Andrew Davies ◽

Simon Rule ◽

Kim M. Linton ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Phase 2, open-label study of CUDC-907 with and without rituximab in patients with relapsed/refractory MYC-altered diffuse large B-cell lymphoma.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps7579 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS7579-TPS7579

Author(s):

Daniel Jeffrey Landsburg ◽

Kevin Kelly ◽

Jaye Viner ◽

Jing Wang ◽

Lucy Gong ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Faculty of 1000 evaluation for Phase II Open Label Study of the oral VEGF-Receptor inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients with Refractory or Relapsed Diffuse Large B Cell Lymphoma.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717995403.793474246 ◽

2013 ◽

Author(s):

Nicolas Mounier

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Vegf Receptor ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Large B Cell Lymphoma ◽

Large B Cell ◽

Receptor Inhibitor

Download Full-text

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access (EA) and Commercial out-of-Specification (OOS) Product

Transplantation and Cellular Therapy ◽

10.1016/s2666-6367(21)00524-8 ◽

2021 ◽

Vol 27 (3) ◽

pp. S408

Author(s):

Caron A. Jacobson ◽

Frederick L. Locke ◽

David B. Miklos ◽

Julie M. Vose ◽

Yi Lin ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Expanded Access ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(20)30120-4 ◽

2020 ◽

Vol 7 (7) ◽

pp. e511-e522 ◽

Cited By ~ 15

Author(s):

Nagesh Kalakonda ◽

Marie Maerevoet ◽

Federica Cavallo ◽

George Follows ◽

Andre Goy ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Large B Cell Lymphoma ◽

Open Label Phase ◽

Large B Cell

Download Full-text

A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps2595 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS2595-TPS2595 ◽

Cited By ~ 6

Author(s):

Timothy Anthony Yap ◽

Peter W. M. Johnson ◽

Jane Winter ◽

John Leonard ◽

Lisa Giulino-Roth ◽

...

Keyword(s):

Multiple Myeloma ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Large B Cell Lymphoma ◽

Hodgkin's Lymphomas ◽

Transformed Follicular Lymphoma ◽

Large B Cell

Download Full-text

NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY

Hematological Oncology ◽

10.1002/hon.114_2629 ◽

2019 ◽

Vol 37 ◽

pp. 157-158

Author(s):

P.L. Zinzani ◽

A. Santoro ◽

G. Gritti ◽

P. Brice ◽

P.M. Barr ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Brentuximab Vedotin ◽

Phase 2 ◽

Efficacy And Safety ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Nivolumab Combined with Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL): Efficacy and Safety Results from the Phase 2 CheckMate 436 Study

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2019.07.262 ◽

2019 ◽

Vol 19 ◽

pp. S303

Author(s):

Pier Luigi Zinzani ◽

Armando Santoro ◽

Guiseppe Gritti ◽

Pauline Brice ◽

Paul M. Barr ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Brentuximab Vedotin ◽

Phase 2 ◽

Efficacy And Safety ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma

Leukemia & Lymphoma ◽

10.3109/10428194.2013.784969 ◽

2013 ◽

Vol 54 (12) ◽

pp. 2627-2630 ◽

Cited By ~ 5

Author(s):

Danielle Brander ◽

David Rizzieri ◽

Jon Gockerman ◽

Louis Diehl ◽

Thomas Charles Shea ◽

...

Keyword(s):

Cell Lymphoma ◽

Growth Factor Receptor ◽

B Cell Lymphoma ◽

Vascular Endothelial ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Large B Cell Lymphoma ◽

Endothelial Growth Factor ◽

Large B Cell

Download Full-text

Faculty Opinions recommendation of Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718389157.793521335 ◽

2016 ◽

Author(s):

Won Seog Kim

Keyword(s):

Elderly Patients ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Phase 2 ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

S1601 NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM THE PHASE 2 CHECKMATE 436 STUDY

HemaSphere ◽

10.1097/01.hs9.0000564652.16751.86 ◽

2019 ◽

Vol 3 (S1) ◽

pp. 737

Author(s):

P.L. Zinzani ◽

A. Santoro ◽

G. Gritti ◽

P. Brice ◽

P.M. Barr ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Brentuximab Vedotin ◽

Phase 2 ◽

Efficacy And Safety ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text